StreetInsider.com News Articles

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate in a fireside chat at 9:40 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address

Form SD AbbVie Inc.

Mon, 01 Jun 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26585043.html

Form SD AbbVie Inc.

Mon, 01 Jun 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26585043.html

AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations

Fri, 29 May 2026 08:00:44 -0400

AbbVie Inc. (NYSE: ABBV) received European Commission authorization to expand the label for its cancer drug VENCLYXTO to include additional combination treatments for previously untreated chronic lymphocytic leukemia patients.

The authorization allows VENCLYXTO (venetoclax) to be used in combination with acalabrutinib, with or without obinutuzumab, and in combination with ibrutinib for treating adult patients with previously untreated CLL. The approval extends to all European Union member states, as well as Iceland, Norway and Liechtenstein.

The expanded label was supported by data from three clinical trials: the Phase 3 AMPLIFY trial for the acalabrutinib combination, the Phase 3 GLOW trial for the ibrutinib

AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations

Fri, 29 May 2026 08:00:44 -0400

The expanded label was supported by data from three clinical trials: the Phase 3 AMPLIFY trial for the acalabrutinib combination, the Phase 3 GLOW trial for the ibrutinib

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia